1. Home
  2. SAFT vs CMPX Comparison

SAFT vs CMPX Comparison

Compare SAFT & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Safety Insurance Group Inc.

SAFT

Safety Insurance Group Inc.

HOLD

Current Price

$73.10

Market Cap

1.1B

Sector

Finance

ML Signal

HOLD

Logo Compass Therapeutics Inc.

CMPX

Compass Therapeutics Inc.

HOLD

Current Price

$5.45

Market Cap

927.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SAFT
CMPX
Founded
1979
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
927.5M
IPO Year
2002
2020

Fundamental Metrics

Financial Performance
Metric
SAFT
CMPX
Price
$73.10
$5.45
Analyst Decision
Strong Buy
Analyst Count
0
9
Target Price
N/A
$14.43
AVG Volume (30 Days)
69.5K
1.8M
Earning Date
05-06-2026
05-07-2026
Dividend Yield
5.03%
N/A
EPS Growth
40.17
N/A
EPS
6.70
N/A
Revenue
$1,263,732,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$677.91
P/E Ratio
$10.92
N/A
Revenue Growth
12.83
N/A
52 Week Low
$67.04
$1.40
52 Week High
$84.20
$6.88

Technical Indicators

Market Signals
Indicator
SAFT
CMPX
Relative Strength Index (RSI) 46.25 49.44
Support Level $70.94 $4.86
Resistance Level $74.12 $5.77
Average True Range (ATR) 1.50 0.29
MACD 0.18 0.04
Stochastic Oscillator 55.05 72.50

Price Performance

Historical Comparison
SAFT
CMPX

About SAFT Safety Insurance Group Inc.

Safety Insurance Group Inc is a provider of private passenger automobile, commercial automobile, and homeowners insurance in Massachusetts. The company also offers property and casualty insurance products, including commercial automobiles, homeowners, dwelling fire, umbrella, and business owner policies. The company operates in the business segment of Property and casualty insurance operations.

About CMPX Compass Therapeutics Inc.

Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.

Share on Social Networks: